Idiopathic facial paralysis: new therapeutic prospects with acetyl-L-carnitine.
The study population was composed of 43 patients affected by idiopathic facial paralysis (20 males and 23 females), aged between 11 and 67. The study was carried out in a double-blind, randomized, placebo controlled manner. Acetyl-L-carnitine was given in an oral dose of 3 x 1 g daily for 1 month, along with a daily oral administration of 50 mg of methylprednisolone for 14 days. The evaluation was made by means of electromyograms (EMG) of the orbicularis oculi and oris muscles, by the Schirmes lacrimation test, by stapedial reflex test and a score scale for clinical assessment of paralysis. Results so far obtained have shown an earlier functional recovery of the nerve in those patients treated with acetyl-L-carnitine. Comparison between the affected and unaffected sides of the face revealed a statistical significance in the treated group (p < 0.05) as well as the amplitudes of the muscle action potentials (MAP) between the affected sides (p < 0.01).
Mezzina
C
C
Neurological Department, Hospital Mestre, Venice, Italy.
De Grandis
D
D
Calvani
M
M
Marchionni
A
A
Pomes
A
A
D000108:Acetylcarnitine / Q000494:pharmacology / Q000627:therapeutic use*; D000200:Action Potentials / Q000187:drug effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004311:Double-Blind Method; D005158:Facial Paralysis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000108:Acetylcarnitine